Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
- Written by PR Newswire
![]() |
- Synergistic collaboration to revolutionize age-related therapies worldwide
- Deal valued at over $300 million USD for initial product
MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an exclusive global licensing agreement with pharmaceutical...















